

## **CERTIFICATE OF ANALYSIS**

Important Note:	Centrifuge before opening to ensure complete recovery of vial contents.		
Catalog #:	M66102M	Lot #:	9D11911
Description:	MAb to Osteopontin (NT) Monoclonal Antibody to Human Osteopontin, N-Terminal (N	VT)	
Specificity:	Specific to Osteopontin (OPN) N-terminal (a.a. 1-166). Recognizes native and recombinant OPN. Crossreacts with human and mouse OPN.		
Clone:	2C5		
Host Animal:	Mouse	Isotype:	$IgG_1$
Source:	Ascites		
Immunogen:	Recombinant full-length Osteopontin.		
Format:	Purified, Liquid	Exp. Date:	18 MAR 2016
Purification:	$>$ 90% pure (SDS-PAGE). Protein A Chromatography Product is 0.2 $\mu$ m filtered.		
Concentration:	4.63 mg/mL (OD280nm, $E^{0.1\%} = 1.4$ )		
Buffer:	10 mM Sodium Phosphate, 150 mM Sodium Chloride, pH 7.4 $\pm$ 0.2.		
Preservative:	0.05% Sodium Azide		
Applications:	Suitable for use in ELISA and Western Blot. Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.		



## Titration curve of M66102M in indirect ELISA:

Antigen: Recombinant full-length Osteopontin, coated at  $0.1 \ \mu g/mL$ .

Antibody: Dilution series of M66102M, incubated 2 hours at room temp followed by Goat anti-Mouse IgG:HRP conjugate and TMB substrate.



5171 Wilfong Road Memphis, TN 38134 USA Telephone: 901-382-8716 Fax: 901-333-8223 Email: info@meridianlifescience.com www.MeridianLifeScience.com

Catalog #M66102M Page 2 of 2

Storage:	Short term (up to 7 days) store at 2-8°C. Long term, aliquot and store at -20°C. Avoid multiple freeze/thaw cycles.
Warning:	This product contains sodium azide, which has been classified as Xn (Harmful), in European Directive 67/548/EEC in the concentration range of $0.1 - 1.0$ %. When disposing of this reagent through lead or copper plumbing, flush with copious volumes of water to prevent azide build-up in drains.
References:	The reference listed below is for research purposes only: Plumer, A., et al., (2008), "Development of fragment-specific osteopontin antibodies and ELISA for quantification in human metastatic breast cancer", <u>BMC Cancer</u> , 8:38.

lobut att

24 October 2013 Date

Signature

FOR RESEARCH OR FURTHER MANUFACTURING USE ONLY